Valpromide

Valpromide

Clinical data
ATC code	N03AG02 (WHO)
Identifiers
IUPAC name 2-propylpentanamide
CAS Number	2430-27-5
PubChem CID	71113
DrugBank	EXPT03231
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C8H17NO
Molar mass	143.228 g/mol

Valpromide (marketed as Depamide by sanofi-aventis) is a carboxamide derivative of valproic acid used in the treatment of epilepsy and some affective disorders. It is rapidly metabolised (80%) to valproic acid (another anticonvulsant) but has anticonvulsant properties itself. It may produce more stable plasma levels than valproic acid or sodium valproate and may be more effectively at preventing febrile seizures. However it is over one hundred times more potent inhibitor of liver microsomal epoxide hydrolase. This makes it incompatible with carbamazepine and can affect the ability of the body to remove other toxins. Valpromide is no safer during pregnancy than valproic acid.

Valpromide is formed through the reaction of valproic acid and ammonia via an intermediate acid chloride.

In pure form, valpromide is a white crystalline powder and has melting point 125-126°C. It is practically insoluble in water but soluble in hot water. It is available on the market in some European countries.

References

• The Medical Treatment of Epilepsy by Stanley R Resor. Published by Marcel Dekker (1991). ISBN 0-8247-8549-5.
• Hydrolysis in Drug and Prodrug Metabolism: Chemistry, Biochemistry, and Enzymology by Bernard Testa, Joachim M. Mayer (2003). ISBN 3-906390-25-X.
• In Vitro Methods in Developmental Toxicology by Gary L Kimmel, Devendra M Kochhar, Baumann (1989). ISBN 0-8493-6919-3.
• The Lundbeck Institute Guide to Psychotropics - Valpromide

Template:Pharma-stub